From Blood Cancer Discovery: Intra-Leukemic Interactions Shape #AML Chemoresistance buff.ly/Zl42183

Intra-leukemic interferon signaling suppresses the expansion of leukemic subpopulations and contributes to chemoresistance in several experimental models of AML using primary patient samples. #AMLsm

From the January issue of Blood Cancer Discovery: Tandem Duplications in UBTF Create XPO1-Dependent Nuclear Export Signals that Reveal a Leukemic Therapeutic Dependency buff.ly/mL0KS6a
#AMLsm

High Rates of Vulnerability Identified in AML Patients Aged 60 Years or Older High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with acute myeloid leukemia.

High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with #AML when measured at baseline, prior to receiving intensive chemotherapy. Presented at #ASH2025.

https://bit.ly/4jiQIMH

#leusm #AMLsm #ASH25

🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies.

Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei.

Watch now: 👉 buff.ly/VJJUbmz

#AMLsm #Leusm #Leukemia

In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease.

Watch here:

👉 buff.ly/HbJTfmF 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky

Want to hear highlights from #iwAL25?🩸

Check out our fantastic roundtable discussion with leading experts Harry Erba, Thomas Cluzeau, Marina Konopleva, & Aditi Shastri by clicking here:

👉 buff.ly/wtheBJa 👈

#AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

Want to hear about the evolving role of menin inhibitors in AML?🩸

Don't miss our roundtable discussion on this topic from #iwAL25, featuring leading experts Naval Daver, @leukdocjz.bsky.social, Eytan Stein, & Amir Fathi.

Watch here: 👉 buff.ly/iaEfMsV

#AMLsm #Leusm #HemOnc #BloodSky #HemeSky

#iwAL25 | Charlie Craddock answers YOUR transplantation questions in a special Ask the Expert session!

Watch here:

👉 buff.ly/TRqoc4q%F0%9...

#HemOnc #ImmunoOnc #AMLsm #BMTsm #Leusm #BloodSky #HemeSky #MedSky

At #iwAL25, leading experts Mark Levis, Eunice Wang, and Sanam Loghavi participated in a thought-provoking debate about the value and utility of MRD in the management of adults with newly diagnosed AML.🩸

Watch it here: 👉 buff.ly/XfMfsmQ

#AMLsm #Leusm #MRD #HemOnc #BloodSky #HemeSky #MedSky

🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

Today is #WorldLeukemiaDay.🩸

Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ

Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧

#AMLsm #CLLsm #ALLsm #Leusm

🩸 Today is World #Leukemia Day 🌎

🎥 Musa Yilmaz of @mdanderson.bsky.social discusses the critical role of MRD monitoring in patients with FLT3-mutated AML, as achieving MRD negativity is associated with a lower risk of relapse.

Learn more: 👉 buff.ly/ZYTnlpy

#WorldLeukemiaDay #AMLsm #HemOnc

🎥 Guenther Koehne presents the early findings from the Phase I/II study of donor-derived anti-CD33 CAR T-cells in patients with R/R AML following alloSCT:

👉 buff.ly/ekvp1qv 👈

#AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #BloodSky #HemeSky #MedSky

🎥 Shaun Fleming presents early safety and efficacy findings of LAVA-1266, a CD123-targeting Vγ9Vδ2-T cell engager, in patients with R/R AML or HR-MDS:

👉 buff.ly/GIoMPtN 👈

#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #EHA2025 #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

At #EHA2025, Harry Erba of @dukecancer.bsky.social outlined the updated results from the Phase III QuANTUM-Wild trial evaluating quizartinib combined with chemotherapy and as single-agent maintenance in newly diagnosed FLT3-ITD-negative AML.

Watch here:

👉 buff.ly/hMASdPZ 👈

#AMLsm #Leusm #CTSM

In an interview from #EHA2025, Musa Yilmaz of @mdanderson.bsky.social speaks on the efficacy of the triplet combination of decitabine, venetoclax, & quizartinib in patients with newly diagnosed FLT3-ITD–mutated AML.

Watch now:

🎥 buff.ly/LJGCKLC

#AMLsm #Leusm #Leukemia #CTSM #HemOnc #BloodSky

Watch our recent interview from #EHA2025 with Andrius Žučenka to hear about ADVANCED, a novel conditioning regimen for alloSCT in patients with adverse-risk AML.

Click here:

👉 buff.ly/nhZNbv8 👈

#AMLsm #Leusm #Leukemia #BMTsm #HemOnc #BloodSky #HemeSky #MedSky

We recently caught up with Farhad Ravandi of @mdanderson.bsky.social, who spoke on the current standard of treatment for older or unfit patients with AML and outlined future directions in this patient population.

Watch here:

🎥 buff.ly/t3ELfZa

#AMLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky

🎥 Pinkal Desai of @weillcornell.bsky.social discusses healthcare resource utilization in newly diagnosed patients with AML treated with venetoclax compared with high- or low-intensity non-venetoclax therapies:

👉 buff.ly/O6dmk8i 👈

#AMLsm #Leusm #Leukemia #HemOnc #EHA2025 #MedSky #BloodSky

It was wonderful to catch up with Joshua Zeidner at #EHA2025 to hear the updated results from the Beat AML Master trial of revumenib + aza-ven in older adults with NPM1-mutated or KMT2A-rearranged AML.

Watch here:
👉 buff.ly/sT0CECq

#AMLsm #Leusm #CTSM #BloodSky #HemeSky @leukdocjz.bsky.social

At #EHA2025, we had the opportunity to catch up with Amir Fathi to hear the promising results of the Phase Ib/II KOMET-001 study of ziftomenib in R/R NPM1-mutant AML.

Check out the interview here:

👉 buff.ly/IlVeBKE

#AMLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

🎥 Bruno Paiva comments on the potential of measurable residual disease assessment by multiparameter flow cytometry as a valid early endpoint of treatment efficacy in AML:

👉 buff.ly/79HLTzc 👈

#EHA2025 #AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

An analysis of the QuANTUM-First trial assessed the effect of baseline co-mutations on quizartinib efficacy in AML. 🧬🩸

Learn more by watching our recent interview with Mark Levis here:

👉 buff.ly/YfzHnJe 👈

#AMLsm #Leusm #EHA2025 #CTSM #Leukemia #BloodSky #HemeSky #MedSky

Watch our interview from #EHA2025 with Maria Amaya to hear the results from a clinical study evaluating the safety & efficacy of an all-oral regimen of CC-486 plus venetoclax in AML:

👉 buff.ly/6NXvG6h 👈

#AMLsm #Leusm #Leukemia #CTSM #BloodSky #HemeSky #MedSky

🎥 It was great to hear from Gail Roboz at #EHA2025! Dr Roboz provided insight into hot topics in AML from the meeting, covering menin inhibitors, venetoclax dose adjustments, & maintenance therapy.

Watch here:
👉 buff.ly/KRd1l8i

#AMLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky

At #EHA2025 last week, Amer Zeidan gave an update on immune checkpoint inhibition in MDS & AML, highlighting the promise of novel agents sabatolimab and bexmarilimab.🩸

Watch the interview here:
👉 buff.ly/mVSYBHP

#AMLsm #MDSsm #Leusm #TrialUpdate #ImmunoOnc #BloodSky #HemeSky #CTSM

Another day of our exclusive interviews at #EHA2025 has just kicked off!🎥😃

Gail Roboz provided valuable insights into the treatment landscape of AML & shared the PhI/II results of the all-oral DEC-C plus ven regimen in newly diagnosed patients ineligible for intensive chemotherapy.🩸

#AMLsm #Leusm

Dr Amer Zeidan interviewing with VJHemOnc at EHA 2025

We've had a wonderful first day at #EHA2025! Thank you to Amer Zeidan of @yalecancer.bsky.social, who shared interesting insights into the use of immune checkpoint inhibition in MDS, the KOMET-017 trial, & more!

Stay tuned 👉VJHemOnc.com!

#MDSsm #HemOnc #LeuSM #AMLsm #BloodSky #CTSM #TrialUpdate

#ASCO25 | Uday Popat of @mdanderson.bsky.social‬ presents the results of a Phase I/II study investigating a myeloablative fractionated busulfan conditioning regimen with sorafenib prior to alloSCT in pts with AML.

Click here to watch:
👉 buff.ly/4lUTOLP

#AMLsm #Leusm #CTSM @ascocancer.bsky.social

🎥 At #EBMT25, Prof. Mohamad Mohty discussed the optimization of conditioning regimens for stem cell transplantation in AML and MDS.

Watch the interview here:
👉 buff.ly/G0iAVH1 👈

#BMTsm #AMLsm #Leusm #MDSsm #HemOnc #MedSky #HemeSky #BloodSky